2022
DOI: 10.1016/j.ajem.2022.07.021
|View full text |Cite
|
Sign up to set email alerts
|

Impact of COVID-19 pandemic on STEMI thrombolysis and Emergency Department's performance in a non-PCI capable tertiary hospital

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2025
2025

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 22 publications
0
1
0
Order By: Relevance
“…Thrombolytic drugs are a potential treatment for COVID-19 thrombotic complications ( 80 , 81 ) and ARDS ( 82 ). In China, drugs commonly used for thrombolytic therapy include urokinase, streptokinase, and rt-PA, which promote fibrinolysis by activating plasminogen ( Table 2 , row 13-15).…”
Section: Discussionmentioning
confidence: 99%
“…Thrombolytic drugs are a potential treatment for COVID-19 thrombotic complications ( 80 , 81 ) and ARDS ( 82 ). In China, drugs commonly used for thrombolytic therapy include urokinase, streptokinase, and rt-PA, which promote fibrinolysis by activating plasminogen ( Table 2 , row 13-15).…”
Section: Discussionmentioning
confidence: 99%